Hepatitis C News and Research

Latest Hepatitis C News and Research

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Viewpoints: Budget disappointment; supporting CLASS Act; health law's Medicaid 'mess'

If fiscal sanity is to be restored, Americans need to be told the hard facts — not just that the national debt is out of control and that deficits can't go on and on, but that getting the nation's finances in order will require going everywhere in the budget: domestic programs, defense spending and the big entitlement programs such as Social Security, Medicare and Medicaid that already consume three of every five dollars the government spends.

16 Feb 2011

Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters

Idera Pharmaceuticals, Inc. announced today that it is presenting data on IMO-3100, an antagonist of TLR7 and TLR9, in a preclinical model of lupus showing that treatment with IMO-3100 suppressed several key disease progression parameters.

15 Feb 2011

NIH awards renewal grant to BMC's CARE unit to expand education of physicians-in-training

The Clinical Addiction Research and Education Unit in the Section of General Internal Medicine at BMC was recently awarded a $1,886,087 renewal grant from the National Institutes of Health to expand its education of physicians-in-training to become sophisticated implementers of substance use screening, assessment and treatment research.

14 Feb 2011

Chimerix announces completion of $45 million Series F financing

Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.

14 Feb 2011

Janssen, Medivir collaborate to discover and develop drugs against dengue virus

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today that it has signed a collaboration agreement with Janssen Pharmaceutica N.V. for the discovery and development of drugs for the prophylaxis and treatment of dengue virus infection.

14 Feb 2011

HIV infection in mothers reduces disease resistance in babies: Study

New research suggests that babies whose mothers have HIV, but are not HIV-infected themselves, are born with lower levels of specific proteins in their blood called antibodies, which fight infection, compared with babies not exposed to HIV.

13 Feb 2011

53 share a needle & HIV risk due to a clinic blunder

Over 50 patients at a private radiology clinic were given blood tests using a needle device meant for single-patient use. Authorities have launched an investigation into the matter. These patients are all at risk of hepatitis B, hepatitis C and HIV infection. These cancer patients will need testing for the viruses, and again in three months. They had visited the hospital for a positron emission tomography (PET) scan for cancer detection.

13 Feb 2011

FDA grants Inhibitex Fast Track Designation for INX-189 in treatment of chronic hepatitis C viral infection

Inhibitex, Inc. today reported that the U.S. Food and Drug Administration ("FDA") has designated the investigation of INX-08189, a potent guanosine nucleotide polymerase inhibitor for the treatment of chronic hepatitis C viral infection, as a Fast Track development program.

11 Feb 2011

Richard J. Fasenmyer Foundation awards $3M to Cleveland physicians for AIDS research

A three-year, $3 million gift from the Richard J. Fasenmyer Foundation will fund research by a pair of Cleveland physicians into HIV and the body's response in autoimmune diseases.

11 Feb 2011

Medivir initiates phase 1a clinical trial of TMC649128 for chronic HCV infection

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a phase 1a clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus infection.

10 Feb 2011

Idenix announces updates on HCV and HIV clinical development programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced updates to three clinical development programs.

10 Feb 2011

HIV-negative babies born to HIV-positive mothers have lower antibody levels for some infections, study finds

"Babies who are exposed to HIV at birth but don't become infected with the virus have lower levels of antibodies to diseases such as whooping cough, tetanus and pneumococcus," according to a study published in the Feb. 9 issue of the Journal of the American Medical Association (JAMA), HealthDay News/U.S. News & World Report.

10 Feb 2011

New study shows economic burden of dengue in Western Hemisphere is $2.1 billion per year

Dengue illness, the most common mosquito-borne viral disease in the world, has expanded from its Southeast Asian origins and is resurgent in countries such as Argentina, Chile and the continental United States.

8 Feb 2011

Technique that cleared mouse of HIV-like virus sparks hope for new therapy

In a breakthrough, Australian researchers have developed a method to boost the immune system. This technique is seen to be capable of clearing an “HIV-like” infection from a mouse. This could in future lead to a cure for HIV and other chronic viral infections in humans. The findings from Melbourne’s Walter and Eliza Hall Institute are centred on a naturally occurring cell signalling hormone called interleukin-7 (IL-7).

6 Feb 2011

Roche launches cobas TaqScreen DPX Test for parvovirus B19 and hepatitis A virus

Roche announced today that the cobas® TaqScreen DPX Test for use on the cobas s 201 system is now available in the US. It is the first commercial test to quantify parvovirus B19 and detect hepatitis A virus (HAV) simultaneously in one assay in human plasma.

5 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

Digna Biotech, CIMA receive EU grant for development of gene therapy product for Acute Intermittent Porphyria

Digna Biotech and the Centro de Investigacion Medica Aplicada (CIMA) de la Universidad de Navarra announced today that the European Union (EU) has finalized a EUR 3.3 million grant to AIPGENE consortium. Digna Biotech and CIMA will receive, as members of the consortium, EUR 0.5 and EUR 0.8 million respectively for the clinical development of a gene therapy product for Acute Intermittent Porphyria (AIP).

4 Feb 2011

Cell signaling hormone boosts immune response to clear HIV-like infection

Australian scientists have successfully cleared a HIV-like infection from mice by boosting the function of cells vital to the immune response.

4 Feb 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Viewpoints: Budget disappointment; supporting CLASS Act; health law's Medicaid 'mess'

Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters

NIH awards renewal grant to BMC's CARE unit to expand education of physicians-in-training

Chimerix announces completion of $45 million Series F financing

Janssen, Medivir collaborate to discover and develop drugs against dengue virus

HIV infection in mothers reduces disease resistance in babies: Study

53 share a needle & HIV risk due to a clinic blunder

FDA grants Inhibitex Fast Track Designation for INX-189 in treatment of chronic hepatitis C viral infection

Richard J. Fasenmyer Foundation awards $3M to Cleveland physicians for AIDS research

Medivir initiates phase 1a clinical trial of TMC649128 for chronic HCV infection

Idenix announces updates on HCV and HIV clinical development programs

HIV-negative babies born to HIV-positive mothers have lower antibody levels for some infections, study finds

New study shows economic burden of dengue in Western Hemisphere is $2.1 billion per year

Technique that cleared mouse of HIV-like virus sparks hope for new therapy

Roche launches cobas TaqScreen DPX Test for parvovirus B19 and hepatitis A virus

Merck reports GAAP net income of $861 million for 2010

Digna Biotech, CIMA receive EU grant for development of gene therapy product for Acute Intermittent Porphyria

Cell signaling hormone boosts immune response to clear HIV-like infection

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in